These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 10496649

  • 1. Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase.
    Hu M, Li Y, Davitt CM, Huang SM, Thummel K, Penman BW, Crespi CL.
    Pharm Res; 1999 Sep; 16(9):1352-9. PubMed ID: 10496649
    [Abstract] [Full Text] [Related]

  • 2. Development of Caco-2 cells expressing high levels of cDNA-derived cytochrome P4503A4.
    Crespi CL, Penman BW, Hu M.
    Pharm Res; 1996 Nov; 13(11):1635-41. PubMed ID: 8956327
    [Abstract] [Full Text] [Related]

  • 3. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.
    Raeissi SD, Hidalgo IJ, Segura-Aguilar J, Artursson P.
    Pharm Res; 1999 May; 16(5):625-32. PubMed ID: 10350002
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.
    Brimer C, Dalton JT, Zhu Z, Schuetz J, Yasuda K, Vanin E, Relling MV, Lu Y, Schuetz EG.
    Pharm Res; 2000 Jul; 17(7):803-10. PubMed ID: 10990198
    [Abstract] [Full Text] [Related]

  • 6. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
    Kawahara I, Kato Y, Suzuki H, Achira M, Ito K, Crespi CL, Sugiyama Y.
    Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.
    Katoh M, Nakajima M, Yamazaki H, Yokoi T.
    Eur J Pharm Sci; 2001 Feb; 12(4):505-13. PubMed ID: 11231118
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Molecular characterization of specifically active recombinant fused enzymes consisting of CYP3A4, NADPH-cytochrome P450 oxidoreductase, and cytochrome b5.
    Inui H, Maeda A, Ohkawa H.
    Biochemistry; 2007 Sep 04; 46(35):10213-21. PubMed ID: 17691855
    [Abstract] [Full Text] [Related]

  • 13. Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent.
    Wang RW, Newton DJ, Liu N, Atkins WM, Lu AY.
    Drug Metab Dispos; 2000 Mar 04; 28(3):360-6. PubMed ID: 10681383
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5.
    Patki KC, Von Moltke LL, Greenblatt DJ.
    Drug Metab Dispos; 2003 Jul 04; 31(7):938-44. PubMed ID: 12814972
    [Abstract] [Full Text] [Related]

  • 16. Development of Caco-2 cells co-expressing CYP3A4 and NADPH-cytochrome P450 reductase using a human artificial chromosome for the prediction of intestinal extraction ratio of CYP3A4 substrates.
    Takenaka T, Kazuki K, Harada N, Kuze J, Chiba M, Iwao T, Matsunaga T, Abe S, Oshimura M, Kazuki Y.
    Drug Metab Pharmacokinet; 2017 Feb 04; 32(1):61-68. PubMed ID: 28139373
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3.
    Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Lown KS, Watkins PB.
    Mol Pharmacol; 1997 May 04; 51(5):741-54. PubMed ID: 9145912
    [Abstract] [Full Text] [Related]

  • 19. Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates.
    Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, Miller VP, Crespi CL.
    Drug Metab Dispos; 2000 Dec 04; 28(12):1440-8. PubMed ID: 11095581
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.